Galderma and ZARS extend Pliaglis deal

Switzerland's Galderma Pharma has entered an agreement with USA-based ZARS Pharma giving it exclusive rights for all markets outside the USA and Canada for the promotion and distribution of a novel topical anesthetic cream. This partnership follows an accord signed last year between the two firms for the promotion and distribution of Pliaglis (lidocaine and tetracaine) in the USA and Canada.

"This agreement gives us a new opportunity to contribute to progress in patient care worldwide," said Humberto Antunes, chief executive of Galderma. "As the market for corrective and aesthetic procedures continues to grow, Pliaglis, with its unique vehicle and comfort of use for both patient and doctor is poised to fill an important unmet need. This agreement is part of our strategy to offer a comprehensive range of products that improve corrective and esthetic procedural outcomes and complement our current family of therapeutic prescription and over-the-counter products throughout the world," he added.